Impact of novel N-aryl substituted piperamide on NF-kappa B translocation as a potent anti-neuroinflammatory agent.

NF-kB translocation is the key point in the upstream neuroinflammatory pathways. It plays an import role in the pro-inflammatory chemokine, cytokine, and various enzyme expressions, consequently leading to the inflammatory response of the innate immune system. The NF-kB complex consists of structural homolog subunits, including c-Rel, RelB, p52, p65, and p50. Among the p65 subunit has a vital function of NF-kB translocation and DNA binding. NF-kB translocation may occur due to acetylation and phosphorylation LYS 310 and SER311 amino acids in chain A of the p65 subunit in response to IKK-α/β activity. Therefore, there are two ways to inhibit the NF-kB translocation, either directly blocking the active sites of IKK-α/β enzymes or protecting the LYS 310 and SER311 of p65 subunit from acetylation and phosphorylation. NF-kB translocation inhibitors can maintain the NF-kB complex in the inactive form inside the cytosol. In this study, we have designed and developed an NF-kB translocation inhibitor, D4. We have performed various in silico, in vitro and in situ studies on the anti-neuroinflammatory function of D4. It showed the ability to inhibit IKK-α/β in both genome and proteome levels and protect LYS310 of the p65 subunit of NF-kB from the acetylation process. Therefore, we can suggest D4 as the promising anti-neuroinflammatory agent with a function on the upstream process of inflammatory pathways.

Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.